Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

  • End date
    Sep 28, 2023
  • participants needed
  • sponsor
    Weill Medical College of Cornell University
Updated on 28 January 2021
myelodysplastic/myeloproliferative neoplasm


This study assesses the potential of using a TGF receptor inhibitor for the treatment of anemic patients with myeloproliferetive neoplasms. TGF signaling is known to be abnormally high in patients with myeloproliferative neoplasms and it is thought that abnormal TGF signals cause many of the problems with blood cell formation in these diseases. The study design allows all patients to receive the study drug, vactosertib. The dose of vactosertib is individualized within a pre-set range based upon its effectiveness and tolerability. A total of up to 37 patients will be treated.


This is a two-tiered single arm Phase 2 trial of vactosertib (TEW-7197) for the treatment of anemia in Ph-neg MPNs. Both tiers use a rule-based, accelerated dose escalation scheme to efficiently assess the potential of vactosertib to safely and effectively treat anemic patients with Ph-neg MPNs. The first tier of this trial (Tier 1) is an intra-patient dose finding study in 12 patients that uses a low starting dose of vactosertib for all patients. For each patent, the treatment dose is escalated according to prospectively-defined rules, and a toxicity and treatment effect algorithm during the period of 16 weeks (4 treatment cycles). If pre-established efficacy and safety endpoints are met (section 5.4, section 9.1, section 11.1), then Tier 1 of the study will be followed by a Tier 2 expansion study with an additional 25 patients for a period of 24 weeks (6 treatment cycles).

Vactosertib will be administered as monotherapy and therefore patients must be off cytoreductive therapies such as interferon, ruxolitinib, hydroxyurea, DNA hypomethylating agents or other cytotoxic chemotherapy prior to enrollment for a period of at least 14 days or 5 half-lives, whichever is longer. Supportive care measures including packed red blood cell (PRBC) transfusions for HGB <7g/dL, or symptomatic anemia, will be permitted. Administration of erythropoiesis stimulating agents (ESAs), however, will not be permitted on the trial (patients recruited would have serum EPO >125 U/L above which the benefit of ESAs is not supported).

Condition MYELOPROLIFERATIVE DISORDER, Myeloproliferative Neoplasms, myeloproliferative neoplasm, myeloproliferative disorders
Treatment Vactosertib
Clinical Study IdentifierNCT04103645
SponsorWeill Medical College of Cornell University
Last Modified on28 January 2021


Yes No Not Sure

Inclusion Criteria

Patients who meet the WHO 2016 criteria for a Ph-neg MPN (including PV, ET
Patients with DIPSS Int-2 or High-risk MF (primary of post-PV/ET) must have had inadequate response to ruxolitinib
Patients with PV or ET should be refractory or unresponsive to hydroxyurea, anagrelide or other available therapy
Anemia as defined by HGB < 10 g/dL, or transfusion of 2 packed red blood cell (PRBC) unit within the past 4 weeks with HGB 8.5g/dL
Ineligible, unsuitable or refractoriness to ESA therapy defined as any of the
Serum erythropoietin (EPO) >125 U/L
Proven ESA unsuitability is defined by history of any of the following
Loss of erythroid hematologic improvement while receiving stable or increased ESA dose; or
ESA-attributed toxicity that, in the treating physician's opinion, makes ESA therapy unsuitable for subject
ESA refractoriness defined by lack of erythroid hematologic improvement to ESA:27
Less than 1.5 g/dL increase in hemoglobin after at least 6 weeks of ESA therapy; or
Ongoing transfusion dependence that has not been reduced by > 4U over an 8-week period compared to ESA pre-treatment 8 weeks
Acceptable Cardiovascular status

Exclusion Criteria

Any other serious medical condition which in the Investigator's opinion would preclude safe participation in the study
Patients with history of TIA or stroke within the past 12 months are excluded
Female subjects who are breastfeeding, or intend to breastfeed, during the study or in the 30 days following the last dose of study drug are excluded
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note